Latest news
Carousel content with 6 slides.
![](/images/DSC00271.jpg#joomlaImage://local-images/DSC00271.jpg?width=&height=)
New patient wellbeing programs launched alongside Patient Parliament
![](/images/Karen_Thrussell.png#joomlaImage://local-images/Karen_Thrussell.png?width=776&height=472)
Shedding light on the complexity of sarcoma
![](/images/Sustainability3.png#joomlaImage://local-images/Sustainability3.png?width=909&height=715)
Peter Mac launches Environmental Sustainability Strategy
![](/images/Discovery_no_logo_resize_2.png#joomlaImage://local-images/Discovery_no_logo_resize_2.png?width=800&height=449)
Two clinical researchers awarded 2024 Discovery Partner Fellowships
![](/images/AI_surgery.png#joomlaImage://local-images/AI_surgery.png?width=1110&height=554)
Peter Mac gets $3 million boost for research preventing surgery complications
![](/images/Lev_Katz.jpg#joomlaImage://local-images/Lev_Katz.jpg?width=&height=)
US award for Peter Mac researcher
Peter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in fighting solid cancer tumours.
CAR T-cell therapy is an innovative form of immunotherapy that uses naturally occurring T-cells which form an essential part of the body’s immune system to target and destroy infected cells. These T-cells are collected, re-engineered with the CAR receptor, and then re-infused as a once-off procedure to fight the cancer cells.
This latest Peter Mac-led study – published in Science Translational Medicine this week - uses younger, stem-like T-cells rather than conventional T-cells. In an exciting development, these cells, called T stem-like CAR T-cells, have shown an increased ability to reproduce when carrying the CAR receptor.
Peter Mac Human Immunology Translational Lab Head, Professor Paul Neeson, said this study is a major step towards CAR T-cell therapy being effective in solid cancers.
“While CAR T-cell therapy has been approved in some types of blood cancers like leukaemia, lymphoma and myeloma, the success of CAR T-cells in solid cancers is limited. This is due to factors including poor CAR T-cell expansion, persistence and exhaustion when fighting the tumour,” he said.
“Importantly, these T stem-like CAR T-cells have improved anti-tumour function in the culture dish and in four pre-clinical models. In fact, they completely eradicated pre-existing solid tumours when combined with the immune checkpoint drug anti-PD1.
“Furthermore, they persist long-term, indicating these cells have all the hallmark traits of CAR T-cells which have had outstanding success in blood cancers.”
The study first created a production protocol that generates fully functional stem-like CAR T-cells in an abbreviated six-day period instead of the standard 14 days, opening the door for a more cost-effective and scalable process in the future.
These significant results support the implementation of production strategies to generate stem-like CAR T-cells for clinical use.
“We would aim to use these cells in two paediatric leukaemias that are resistant to treatment. We believe our protocol will harmonise the CAR T-cell product to one that has consistent anti-tumour function and the important ability to persist,” Prof Neeson said.
“Once we show these cells are safe, we will turn our attention to developing this treatment for paediatric solid cancers including osteosarcoma and neuroblastoma.”
This research was conducted in collaboration with the Murdoch Children’s Research Institute, Zero Childhood Cancers, Children’s Cancer Institute Australia and a broad range of oncologists at Peter Mac.
Watch the video CAR T-Cells: Engineered Cancer Killers
Contacts:
For more information contact the Peter Mac Communications team on 0417 123 048.
![](/images/staff/DJ3_8954_MRV2_FS_BrAf-590x620.jpg)
First steps to navigating Peter Mac
Getting started Peter Mac locations Visitor information Accessing telehealth Important contacts Patient and carer support![Image alt text](/images/Peter Mac building and cafes/DJ3_7004_V2_BrAf_FS.jpg)
We offer care that goes beyond treatment
Peter Mac has a wellbeing approach to care. We base this on a fundamental belief that the best cancer care treats the person and the disease. The Wellbeing Centre is a sanctuary for patients, their families and carers. It is a gathering place that is open, accepting and welcoming for all.
Cancer can be hard to deal with and we know that getting treatment is only part of it. You might have other challenges and need help with them. We offer many kinds of help for you, your loved ones, and your carers. Each resource can help you deal with how cancer affects your body, emotions and money.
The Victorian Adolescent and Young Adult Cancer Service is a team of health and other professionals who specialise in the care of young people aged 15 to 25. We work with you and your healthcare team to support you at all stages of the cancer journey, anywhere in Victoria.
You are a carer if you’re taking care of someone with cancer. You might be a family member, friend or neighbour. Our wonderful volunteer service is here to help to make things a little easier for you and the person you’re caring for. They offer a range of support, resources, and items to help you.
The Psychosocial Oncology Program is a multidisciplinary team. This includes clinical psychologists, social workers, PCLNs, and psychiatrists/psychiatric registrars. They assess patients at risk of mental health problems. They will also assess and treat those with current mental health problems.
![Image alt text](/images/Peter Mac building and cafes/DJ3_7004_V2_BrAf_FS.jpg)